Cerevel Therapeutics Holdings, Inc.
CERE · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $7,685,764 | $7,403,096 | $3,438,201 | $4,992,641 |
| - Cash | $320,436 | $990,965 | $155,721 | $175,763 |
| + Debt | $368,301 | $480,778 | $365,606 | $365,983 |
| Enterprise Value | $7,733,629 | $6,892,909 | $3,648,086 | $5,182,861 |
| Revenue | $0 | $8,246 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Gross Profit | -$1,541 | $6,742 | -$1,449 | -$1,353 |
| % Margin | – | 81.8% | – | – |
| EBITDA | -$139,384 | -$128,321 | -$92,145 | -$95,435 |
| % Margin | – | -1,556.2% | – | – |
| Net Income | -$131,912 | -$132,660 | -$96,361 | -$99,535 |
| % Margin | – | -1,608.8% | – | – |
| EPS Diluted | -0.73 | -0.76 | -0.61 | -0.63 |
| % Growth | 3.9% | -24.6% | 3.2% | – |
| Operating Cash Flow | -$119,669 | -$97,420 | -$72,631 | -$77,327 |
| Capital Expenditures | -$271 | -$902 | -$513 | -$2,057 |
| Free Cash Flow | -$119,940 | -$98,322 | -$73,144 | -$79,384 |